News

Latest Press Releases

March 31, 2023

AnHeart Therapeutics Presents Updated Efficacy and Safety of Taletrectinib in Patients with ROS1-Positive Non–Small Cell Lung Cancer

March 13, 2023

AnHeart Therapeutics Announces Acceptance of Abstract for Oral Presentation at the European Lung Cancer Congress (ELCC) 2023

March 9, 2023

AnHeart Therapeutics Announces Publication of Taletrectinib Global Phase 2 Clinical Trial (TRUST-II) Design in Future Oncology

More Press Releases

Latest News Articles

February 2, 2023
Genome Web

Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug

August 23, 2022
Endpoints New

Biotech's 'sugar high' led to a correction, but winter doldrums could make way for a turnaround story this fall

August 5, 2022
Cancer Network

FDA Grants Breakthrough Therapy Designation to Taletrectinib for ROS1+ Non–Small Cell Lung Cancer

More News Articles

Media Contact

Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com